

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No relevant equalities issues were identified during the consultation on the scope

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No equality issues were raised in the submissions, expert statements or ERG report.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

None

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other

groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No.

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
N/a

Approved by Associate Director (name): Elisabeth George

Date: 03 12 2012

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?
--

During consultation on the 2nd appraisal consultation documents a consultee highlighted under the heading 'Unlawful discrimination or groups who will be disadvantaged?' that the *'draft guidance, puts doctors in an indefensible position and lays the NHS wide open to a legal class action by patients that are forced into a surgical procedure [splenectomy] that may not be relevant to, or in fact resolve, their ITP.'*

This comment does not highlight any unlawful discrimination or groups of patients with ITP that could be disadvantaged. The wording of the marketing authorisation for eltrombopag stipulates that eltrombopag should only be used if a person has had a splenectomy or has not had a splenectomy because such surgery is contraindicated. The regulatory agency has stated that the benefit-harm balance for eltrombopag could not be considered favourable for patients for whom a splenectomy remained a therapeutic option.

NICE has to give recommendations in line with the marketing authorisation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations

to promote equality?
N/a

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
N/a

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 22 05 13